GrantRover ↗

← Alle Förderungen

National Institutes of Health · USA

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and… (R01 Clinical Trial Optional)

Full title in the source: Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Offen

Die Einreichungsfrist endet am 7. Januar 2028. Antragsberechtigte Gruppen laut Quelle: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, State governments und 12 weitere.

Frist
7. Januar 2028 (in 418 Tagen)
Fördersumme
Nicht angegeben — siehe offizielle Ausschreibung
Förderquote
Kein Pflicht-Eigenanteil angegeben; Förderquote nicht angegeben
Eigenanteil
Nicht erforderlich
Wahrscheinliche Antragstellende
Gemeinnützige, Hochschulen & Forschung, Öffentliche Stellen, KMU / Start-ups, Unternehmen Aus Quellkategorien oder Programmregeln; maßgeblich ist die Ausschreibung.
Fördergeber
National Institutes of Health
Referenz
PAR-25-145
Assistance Listing (USA)
93.393 Cancer Cause and Prevention Research
Zuletzt geprüft
13. November 2026

Offizielle Ausschreibung öffnen ↗ Frist zum Kalender hinzufügen

Die offiziellen Beschreibungen sind in der Sprache des Fördergebers (meist Englisch); Zusammenfassung und Eckdaten auf dieser Seite sind auf Deutsch.

Über diese Ausschreibung

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Wer kann sich bewerben?

Other Eligible Applicants include the following:

Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Antragstellerkategorien sind nur ein Ausgangspunkt. Über die Antragsberechtigung entscheidet die offizielle Ausschreibung.

Themen

Education Health

So bewerben Sie sich

  1. Read the full notice of funding opportunity (NOFO) linked from the official page: eligibility, cost sharing and evaluation criteria.
  2. Make sure your organisation has an active SAM.gov registration and Unique Entity ID (UEI); registration can take several weeks.
  3. For NIH: the organisation and the principal investigator also need eRA Commons accounts; applications are usually submitted through Grants.gov (for example with ASSIST).
  4. Prepare the required forms, narrative, budget and attachments exactly as the NOFO specifies.
  5. Submit before the deadline and keep the tracking number. Check for amendments before you submit.

From the call text

Who can apply
Not stated in the call text we hold — check the official page
Company stage
Not stated in the call text we hold — check the official page
Single applicant or consortium
Not stated in the call text we hold — check the official page
Where applicants must be based
Not stated in the call text we hold — check the official page
Where to apply
Not stated in the call text we hold — check the official page

Kontakt

National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Offizielle Quellen

Offizielle Ausschreibungsseite · Programmseite des Fördergebers

Die Angaben auf dieser Seite stammen aus der offiziellen Quelle und wurden zuletzt am 13. November 2026 geprüft. Maßgeblich sind immer die Unterlagen des Fördergebers einschließlich späterer Änderungen.

Weitere Ausschreibungen: National Institutes of Health

National Institutes of Health USA

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High… (R34 Clinical Trial Required)

PAR-25-274

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychologic…

National Institutes of Health USA

Investigator Initiated Clinical Trials of Complementary and Integrative… (R01 Clinical Trial Required)

PAR-25-268

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy…

National Institutes of Health USA

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

PAR-25-158

This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The inten…